Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials
Circulation: Cardiovascular Interventions · 2024
DOI: 10.1161/circinterventions.122.013000 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2024. Verfasst von Carlos M Campos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Heart Institute (InCor), University of São Paulo Medical School, Brazil (C.M.C., L.A.H., R.K.F., A.A.). Hauptthemen laut MEDLINE: Drug-Eluting Stents, Percutaneous Coronary Intervention, Myocardial Infarction, Stroke. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Oncological patients with coronary artery disease face an elevated risk of hemorrhagic and ischemic events following percutaneous coronary intervention. Despite medical guidelines recommending minimal dual antiplatelet therapy (DAPT) duration for patients with cancer, dedicated data on abbreviated DAPT in this population is lacking. This study aims to evaluate the occurrence of ischemic and hemorrhagic events in patients with cancer compared with other high-bleeding risk individuals. METHODS: Patient-level data from 4 high-bleeding risk coronary drug-eluting stent studies (ONYX One, LEADERS FREE, LEADERS FREE II, and SENIOR trials) treated with short DAPT were analyzed. The comparison focused on patients with high-bleeding risk with and without cancer, assessing 1-year rates of net adverse clinical events (all-cause death, myocardial infarction, stroke, revascularization, and Bleeding Academic Research Consortium [BARC] types 3 to 5 bleeding) and major adverse clinical events (all-cause death, myocardial infarction, stroke). RESULTS: A total of 5232 patients were included, of whom 574 individuals had cancer, and 4658 were at high-bleeding risk without previous cancer. Despite being younger with fewer risk factors, patients with cancer had higher net adverse clinical event (HR, 1.25; P =0.01) and major adverse clinical event (HR, 1.26; P =0.02), primarily driven by all-cause mortality and major bleeding (BARC 3–5), but not myocardial infarction, stroke, stent thrombosis, or repeat revascularization. Cancer was an independent predictor of net adverse clinical event ( P =0.005), major adverse clinical event ( P =0.01), and major bleeding ( P =0.03). CONCLUSIONS: The present work is the first report on abbreviated DAPT dedicated to patients with cancer. Cancer is a major marker of adverse outcomes and these events had high lethality. Despite short DAPT, patients with cancer experienced higher rates of major bleeding compared with patients without cancer with high-bleeding risk, which occurred mainly after DAPT discontinuation. These findings reinforce the need for a more detailed and individualized stratification of those patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT03344653, NCT01623180, NCT02843633, NCT0284.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Institute (InCor), University of São Paulo Medical School, Brazil (C.M.C., L.A.H., R.K.F., A.A.).
- Instituto Prevent Senior, Sao Paulo, Brazil (C.M.C.).
- Division of Cardiology (R.M.), Icahn School of Medicine at Mount Sinai, New York, New York.
- Policlinico "G. Rodolico-San Marco," University of Catania, Italy (D.C.).
- London School of Hygiene and Tropical Medicine, United Kingdom (R.O.).
- Department of Cardiology, Inselspital (S.W.), Bern University Hospital, University of Bern, Switzerland.
ORCID-Profile: Carlos M Campos, Roxana Mehran, Davide Capodanno, Ruth Owen, Stephan Windecker, Olivier Varenne, Gregg W Stone, Marco Valgimigli, Roberto Kalil Filho, Keith Oldroyd, Alexandre Abizaid
Zitieren
APA
Campos, C. M., Mehran, R., Capodanno, D., Owen, R., Windecker, S., Varenne, O., Stone, G. W., Valgimigli, M., Hajjar, L. A., Kalil Filho, R., Oldroyd, K., Morice, M. C., Urban, P., & Abizaid, A. (2024). Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.122.013000
Vancouver
Campos CM, Mehran R, Capodanno D, Owen R, Windecker S, Varenne O, et al. Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials. Circulation: Cardiovascular Interventions. 2024. doi:10.1161/circinterventions.122.013000
BibTeX
@article{Campos2024,
author = {Campos, Carlos M and Mehran, Roxana and Capodanno, Davide and Owen, Ruth and Windecker, Stephan and Varenne, Olivier and Stone, Gregg W and Valgimigli, Marco and Hajjar, Ludhmila Abrahão and Kalil Filho, Roberto and Oldroyd, Keith and Morice, Marie-Claude and Urban, Philip and Abizaid, Alexandre},
title = {Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials},
journal = {Circulation: Cardiovascular Interventions},
year = {2024},
doi = {10.1161/circinterventions.122.013000}
}
EUVIMED